Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

p53 Mutations in Human Cancers

1991 • 8,133 citations

Surfing the p53 network

2000 • 6,487 citations

Tolerance, Danger, and the Extended Family

1994 • 4,654 citations

Cancer genes and the pathways they control

2004 • 4,172 citations

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

1994 • 3,536 citations

Live or let die: the cell's response to p53

2002 • 3,138 citations

The tumor microenvironment and its role in promoting tumor growth

2008 • 2,152 citations

Regulatory T cells, tumour immunity and immunotherapy

2006 • 2,009 citations

Immunosuppressive networks in the tumour environment and their therapeutic relevance

2005 • 1,990 citations

The Central Role of CD4+ T Cells in the Antitumor Immune Response

1998 • 1,332 citations

Progress in human tumour immunology and immunotherapy

2001 • 1,327 citations

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

2006 • 1,180 citations

Immunogenic and tolerogenic cell death

2009 • 1,075 citations

Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

2001 • 1,033 citations

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

2005 • 998 citations

Dendritic cell immunotherapy: mapping the way

2004 • 948 citations

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

2007 • 728 citations

Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

1991 • 619 citations

DC-based cancer vaccines

2007 • 581 citations

The anticancer immune response: indispensable for therapeutic success?

2008 • 556 citations

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

2008 • 550 citations

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

2005 • 486 citations

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

2010 • 438 citations

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

2010 • 435 citations

Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

2006 • 428 citations

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

2004 • 368 citations

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

2008 • 360 citations

Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway

2010 • 353 citations

Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

2008 • 321 citations

Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma

2009 • 311 citations

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

2010 • 297 citations

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53

1993 • 267 citations

CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity

2007 • 254 citations

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

2008 • 242 citations

Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF

2009 • 241 citations

Critical Influences of the Cytokine Orchestration on the Outcome of Myelin Antigen‐Specific T‐Cell Autoimmunity in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis

1995 • 239 citations

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

2010 • 229 citations

Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

1997 • 215 citations

Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers

1994 • 213 citations

Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment

2007 • 213 citations

Cancer Vaccines: Moving Beyond Current Paradigms

2007 • 213 citations

Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.

1996 • 208 citations

Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

2009 • 202 citations

Superior induction of anti‐tumor CTL immunity by extended peptide vaccines involves prolonged, DC‐focused antigen presentation

2008 • 197 citations

Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy

2008 • 195 citations

Selective Depletion of CD4+CD25+Foxp3+ Regulatory T Cells by Low-Dose Cyclophosphamide Is Explained by Reduced Intracellular ATP Levels

2010 • 193 citations

Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function

2002 • 190 citations

Chemotherapy and radiotherapy: Cryptic anticancer vaccines

2010 • 189 citations

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

2006 • 188 citations

A Distinct Subset of Self-Renewing Human Memory CD8+ T Cells Survives Cytotoxic Chemotherapy

2009 • 169 citations

Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer

2009 • 168 citations

Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo

2007 • 163 citations

Design and development of synthetic peptide vaccines: past, present and future

2007 • 147 citations

Enhancement of Tumor Outgrowth Through CTL Tolerization After Peptide Vaccination Is Avoided by Peptide Presentation on Dendritic Cells

1998 • 145 citations

B Cells Directly Tolerize CD8+ T Cells

1998 • 142 citations

Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial

2009 • 139 citations

p53 antibodies in patients with various types of cancer: assay, identification, and characterization.

1995 • 134 citations

Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/− Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-α2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696

2009 • 134 citations

Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals

2010 • 133 citations

Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors

2009 • 131 citations

Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC

2010 • 122 citations

Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy

2006 • 114 citations

Targeted Therapies to Improve Tumor Immunotherapy

2008 • 114 citations

Identification of T-cell epitopes for cancer immunotherapy

2007 • 113 citations

Vaccination with p53-peptide?pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

2004 • 107 citations

Novel multi‐peptide vaccination in Hla‐A2+ hormone sensitive patients with biochemical relapse of prostate cancer

2009 • 107 citations

CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?

2008 • 104 citations

T-regulatory cell modulation: the future of cancer immunotherapy?

2009 • 103 citations

Recombinant viruses as a tool for therapeutic vaccination against human cancers

2000 • 99 citations

Peptide-based cancer vaccines

1996 • 97 citations

Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers

2007 • 97 citations

Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.

2002 • 91 citations

Recombinant viral vectors: Cancer vaccines

2006 • 87 citations

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

2010 • 80 citations

Expression of sperm protein 17 (Sp17) in ovarian cancer

2004 • 76 citations

NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells

2009 • 75 citations

Recent advances in strategies for immunotherapy of human papillomavirus‐induced lesions

2007 • 71 citations

Combined modality immunotherapy and chemotherapy: a new perspective

2008 • 69 citations

Antigen‐specific immunotherapy of cervical and ovarian cancer

2008 • 63 citations

P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells.

2003 • 62 citations

Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer

2001 • 60 citations

Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.

2008 • 59 citations

Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.

2002 • 57 citations

Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man

2002 • 56 citations

Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen

2008 • 54 citations

Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients

2003 • 48 citations

Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma

2010 • 42 citations

Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival

2009 • 36 citations

Disruption of TGF-β Signaling Prevents the Generation of Tumor-Sensitized Regulatory T Cells and Facilitates Therapeutic Antitumor Immunity

2009 • 35 citations

Immunologic aspect of ovarian cancer and p53 as tumor antigen

2005 • 34 citations

Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer

2010 • 27 citations

Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2

2008 • 25 citations

Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies

2009 • 24 citations

Presence of Low Dose of Fludarabine in Cultures Blocks Regulatory T Cell Expansion and Maintains Tumor-Specific Cytotoxic T Lymphocyte Activity Generated with Peripheral Blood Lymphocytes

2008 • 23 citations

Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition

2007 • 22 citations

In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.

2002 • 22 citations

Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy

2004 • 13 citations

A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients

2007 • 9 citations

Abstract 2414: Comparable effect of p53 peptide vaccine in adjuvant or pulsed on dendritic cells in ovarian cancer patients: A gynecologic oncology group study

2010 • 1 citations